{"entity":{"id":"nct06459973","kind":"trial","name":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of intravenous (IV) infusion in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"A Clinical Study of YL205 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06459973 by MediLink Therapeutics (Suzhou) Co., Ltd., with 252 participants planned, started 2024-06-04 and due to reach its primary completion in 2027-07-31. Interventions recorded: intravenous (IV) infusion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06459973","url":"https://clinicaltrials.gov/study/NCT06459973"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06459973","phase":"1/2","setting":"A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of YL205 in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","enrolled":252,"outcomes":[]},"route":"/trials/nct06459973/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}